High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules

被引:58
作者
Benmohamed, L
Thomas, A
Bossus, M
Brahimi, K
Wubben, J
Gras-Masse, H
Druilhe, P
机构
[1] Inst Pasteur, Unite Parasitol Biomed, F-75015 Paris, France
[2] Biomed Primate Res Ctr, Dept Parasitol, NL-2288 GJ Rijswijk, Netherlands
[3] Inst Pasteur, CNRS, URA 1309, Lab Chim Biomol, F-59019 Lille, France
关键词
immunogenicity; lipopeptides; Plasmodium falciparum;
D O I
10.1016/S0264-410X(00)00068-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have investigated the immunogenicity in chimpanzees of twelve synthetic peptides derived from four new Plasmodium falciparum molecules expressed at pre-erythrocytic stages of the human malaria parasite. These parasite molecules were initially selected through their ability to be recognized by stage restricted human antibodies. Twelve 20- to 41-mer peptides representing potential human B- or T-cell epitopes were selected from these proteins, and synthesized. Six of these were modified by a C-terminal lipidic chain in order to re-inforce their immunogenicity. Strong B- and T-helper cell responses were induced in chimpanzees by lipopeptides injected without adjuvant and by peptides in Montanide. All twelve peptides induced CD4(+) T-cell proliferative responses, as well as the secretion of IFN-gamma (some of them at very high levels) and eleven peptides induced antibody responses. The immune responses elicited in this way were reactive with native parasite proteins, as shown by recall studies with sporozoite stage proteins, and proved to be long-lasting (up to 10 months after immunization). Our results support the strategy employed to select these four new malarial antigens and the corresponding peptides, and suggest that the immunizing formulations are both efficient and clinically acceptable. (C) 2000 Elsevier Science Ltd, All rights reserved.
引用
收藏
页码:2843 / 2855
页数:13
相关论文
共 61 条
[31]  
HAYNES BF, 1982, SCIENCE, V215, P298, DOI 10.1126/science.6171885
[32]   Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes [J].
Heppner, DG ;
Gordon, DM ;
Gross, M ;
Wellde, B ;
Leitner, W ;
Krzych, U ;
Schneider, I ;
Wirtz, RA ;
Richards, RL ;
Trofa, A ;
Hall, T ;
Sadoff, JC ;
Boerger, P ;
Alving, CR ;
Sylvester, DR ;
Porter, TG ;
Ballou, WR .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (02) :361-366
[33]   SAFETY AND IMMUNOGENICITY IN MAN OF A SYNTHETIC PEPTIDE MALARIA VACCINE AGAINST PLASMODIUM-FALCIPARUM SPOROZOITES [J].
HERRINGTON, DA ;
CLYDE, DF ;
LOSONSKY, G ;
CORTESIA, M ;
MURPHY, JR ;
DAVIS, J ;
BAQAR, S ;
FELIX, AM ;
HEIMER, EP ;
GILLESSEN, D ;
NARDIN, E ;
NUSSENZWEIG, RS ;
NUSSENZWEIG, V ;
HOLLINGDALE, MR ;
LEVINE, MM .
NATURE, 1987, 328 (6127) :257-259
[34]   OVERLAPPING T-CELL EPITOPES IN THE GROUP-I ALLERGEN OF DERMATOPHAGOIDES SPECIES RESTRICTED BY HLA-DP AND HLA-DR CLASS-II MOLECULES [J].
HIGGINS, JA ;
THORPE, CJ ;
HAYBALL, JD ;
OHEHIR, RE ;
LAMB, JR .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 93 (05) :891-899
[35]  
HOFFMAN SL, 1996, MALARIA VACCINE DEV, P40
[36]  
KABILAN L, 1998, P NATL ACAD SCI USA, V85, P5658
[37]   Local protein instability predictive of helper T-cell epitopes [J].
Landry, SJ .
IMMUNOLOGY TODAY, 1997, 18 (11) :527-532
[38]  
MARCHAND C, 1990, B WORLD HEALTH ORGAN, V68, P158
[39]   Malaria disaster in Africa [J].
Marsh, K .
LANCET, 1998, 352 (9132) :924-924
[40]  
MARTINON F, 1992, J IMMUNOL, V149, P3416